Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0012459 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Céline Nourrisson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology-Mycology Department, CHU Clermont-Ferrand, 3IHP, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antibodies, Fungal, Encephalitozoon, Encephalitozoonosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Ligue contre le Cancer 63/03, Ligue Contre le Cancer, Inserm.
Abstract (Originalsprache)
Background The prevalence of microsporidiosis in the general population, or within specific groups of individuals/patients, is largely underestimated. The absence of specific seroprevalence tools limits knowledge of the epidemiology of these opportunistic pathogens, although known since the 1980s. Since microsporidia hijack the machinery of its host cell and certain species multiply within intestinal cells, a potential link between the parasite and colorectal cancer (CRC) has been suggested. Methodology/principal findings To explore a potential epidemiological link between microsporidia and CRC, we evaluated the seroprevalence of Encephalitozoon intestinalis among CRC patients and healthy subjects using ELISA assays based on two recombinant proteins, namely rEiPTP1 and rEiSWP1, targeting polar tube and spore wall proteins. ELISA were performed in 141 CRC patients and 135 healthy controls. Patients with CRC had significantly higher anti-rEiPTP1 IgG levels than subjects in the control group. Anti-rEiPTP1 IgG, anti-rEiSWP1 IgG and anti-rEiPTP1 IgA levels were significantly increased among men with CRC compared to healthy men. Women with CRC who had died had higher rEiSWP1 IgG levels than those who were still alive. Conclusions/Significance These higher antibody levels against microsporidia in patients with CRC suggest a relationship between microsporidia and pathophysiology of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Parasitology-Mycology Department, CHU Clermont-Ferrand, 3IHP, Clermont-Ferrand, France.
- Clermont Auvergne University, « Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte » M2iSH, UMR INSERM 1071, INRAe 1382, Clermont-Ferrand, France.
- National Reference Center (NRC) for cryptosporidiosis, microsporidia and other digestive protozoa, Clermont-Ferrand, France.
- Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.
- Digestive Oncology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
- Digestive Surgery Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
ORCID-Profile: Céline Nourrisson, Philippe Poirier
Förderung
- La Ligue contre le Cancer 63/03
- Ligue Contre le Cancer
- Inserm
- INRAE
Zitieren
APA
Nourrisson, C., Moniot, M., Vercruysse, L., Bonnin, V., Pereira, B., Barnich, N., Bonnet, M., Jary, M., Pezet, D., Gagnière, J., & Poirier, P. (2024). Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012459
Vancouver
Nourrisson C, Moniot M, Vercruysse L, Bonnin V, Pereira B, Barnich N, et al. Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012459
BibTeX
@article{Nourrisson2024,
author = {Nourrisson, Céline and Moniot, Maxime and Vercruysse, Leslie and Bonnin, Virginie and Pereira, Bruno and Barnich, Nicolas and Bonnet, Mathilde and Jary, Marine and Pezet, Denis and Gagnière, Johan and Poirier, Philippe},
title = {Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0012459}
}
EUVIMED